Pharmacodynamic effects of MLN4924, a novel NAE inhibitor, on blood and skin.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Oncology

• Publication date

  2009-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2009.27.15_SUPPL.2562PMID 27961887
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Blockage of neddylation modification stimulates tumor sphere formation in vitro and stem cell differentiation and wound healing in vivo

  2016cites this paper
• Pevonedistat (MLN4924), a First‐in‐Class NEDD8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study

  2015cites this paper
• Targeting protein neddylation: a novel therapeutic strategy for the treatment of cancer

  2011cites this paper